BridgeBio Pharma (NASDAQ:BBIO) Given New $54.00 Price Target at Bank of America
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price objective raised by equities researchers at Bank of America from $50.00 to $54.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Bank of America‘s target price would suggest a potential upside of 19.68% from the […]
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price objective raised by equities researchers at Bank of America from $50.00 to $54.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Bank of America‘s target price would suggest a potential upside of 19.68% from the […]
-logo-1200x675.png?v=20210506080109&w=240&h=240&zc=2){kind=logo}
